Video wird geladen...

Video konnte nicht geladen werden

Zur Startseite

🧵 Elon: “Longevity is an extremely solvable problem” At Vitalist Bay (May 14 - May 17), we’re solving it! 1K+ pioneers, 100+ speakers, 50+ workshops, 40+ activities, 5 critical health tests Join us to spark dozens of SpaceXs for longevity!

6,866,470 Aufrufe • vor 6 Monaten •via X (Twitter)

0 Kommentare

Keine Kommentare verfügbar

Kommentare vom Original-Post werden hier angezeigt

Ähnliche Videos

Today’s guest on the Free Radicals podcast is Michael Ringel, JD PhD, COO Life Biosciences and former Managing Director at Boston Consulting Group. Michael is a leader in longevity and pharma who spent 25+ years advising top pharma companies on their R&D strategy. He is now COO at Life Biosciences where he is bringing the first ever partial epigenetic reprogramming therapy to human clinical trials - a major milestone for the longevity industry. In this episode, we discuss Michael’s insightful paper on why aging is an optimization by evolution, why that means it’s malleable, and how to push the longevity field forward. Michael also sits on the US board of Hevolution Foundation and on the board of the AFAR. Be sure to follow me and Eric Dai to stay up to date on the latest news in longevity biotech! 0:00 Intro 2:30 Why aging is an optimization by evolution 15:10 Why scientists miss the role of evolution in aging 19:31 Evidence that aging is a regulated process 24:40 Hormesis and adaptive stress responses 28:55 The promise of partial epigenetic reprogramming in humans 35:08 Life Bio's first therapy proceeding to clinical trials 47:47 Why targeting the eye, particularly glaucoma and NION, is a strategic choice 52:03 The pharma industry's perspective on anti-aging research 56:39 The importance of public engagement for funding and policy change 1:05:42 Reasons for optimism in longevity 1:08:26 Advice on how to have an impactful and interdisciplinary career 1:11:54 The ethical case for longevity 1:17:34 Concrete steps for audience members to support longevity research

Daniel Shur

16,988 Aufrufe • vor 4 Monaten

According to reports by Punch Newspaper, the President reportedly advised media leaders to remove stories about terrorism from newspaper front pages. If that is indeed the proposal, it raises an important question: can reducing the visibility of terrorism in the media contribute meaningfully to solving the insecurity facing the country? The fundamental issue is that terrorism is not a media problem; it is a security problem. Removing reports from front pages does not remove terrorists from our forests, communities, or highways. It does not address the root causes of insecurity, nor does it bring relief to victims and affected families. A lasting solution requires confronting and defeating those responsible for the violence, restoring security in vulnerable areas, and ensuring that citizens can live without fear. Public awareness of the problem may be uncomfortable, but obscuring it is not the same as solving it. Of course, the President has access to intelligence and security briefings that many of us do not, and he may have reasons for believing this approach could be helpful. However, from my perspective, it is difficult to see how reducing media coverage of terrorism advances the broader goal of ending the threat itself. Perhaps there are considerations unknown to the public. If so, one can only hope that they form part of a comprehensive strategy that delivers real and lasting security for Nigerians. May God protect us all, and may our efforts remain focused on addressing the problem itself rather than merely reducing its visibility. God bless the Federal Republic of Nigeria. 🇳🇬

JusticeCrack

33,783 Aufrufe • vor 1 Monat

David Sinclair's lab may have just found the $100 pill that reverses aging. Over the holidays, his team ran what he calls a "hail mary experiment." They gave old mice a "longevity" cocktail three times a week for 4 weeks. He didn't reveal what's in it - only that it contained molecules that work on the four longevity pathways that control the epigenome. They weren't expecting any significant results. Yet every treated mice came back physiologically younger while the controls didn't. Biological age clocks confirmed the reversal. This changes the trajectory for longevity medicine. The gene therapy his company is taking into human trials costs over $10 million to manufacture per batch. It requires a direct injection into the target organ. These oral molecules cost roughly $100 for a month's course. If they're able to put these molecules into a pill that patients can take instead of them using a multi-million dollar gene therapy, they'd save a ton of money. "Imagine in 10 years you just take a pill for 4 weeks and you get younger. That's what we're headed towards. I can see how this is going to happen." The proof of concept exists in animals. Now it's a race to get it into humans. — David Sinclair (David Sinclair) on Peter Diamandis' (Peter H. Diamandis, MD) Moonshots podcast PS. David Sinclair is speaking at SynBioBeta on May 6th this year, discussing the science of slowing and reversing aging. If longevity is the world you're in, the investors, partners, and scientists shaping this space will be in the room. You won't want to miss it:

John Cumbers

56,136 Aufrufe • vor 3 Monaten